ArticleAMB Express2026
Enzymatic preparation of epigallocatechin gallate diglucoside and bioactivity assessment.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Epigallocatechin gallate (EGCG), the predominant catechin in green tea, has limited application due to its poor water solubility and instability. To address these issues, this study utilized recombinant sucrose phosphorylase to catalyze the glucosylation of EGCG, successfully synthesizing (-)-epigallocatechin gallate 4',4″-O-α-D-diglucopyranoside (EGCG-2G). The process was optimized using response surface methodology, achieving a 97.46% conversion rate of EGCG. EGCG-2G was purified to ≥ 99% purity by semi-preparative liquid chromatography. It exhibited approximately 124-fold higher water solubility than EGCG and demonstrated significantly enhanced stability under thermal and acidic conditions (50 °C, pH = 5), with an 84.82% and 35.36% improvement over EGCG and commercial (-)-epigallocatechin-3-gallate-4'-O-α-D-glucoside (EGCG-1G), respectively. Furthermore, EGCG-2G displayed notable antioxidant, anti-inflammatory, and anti-melanogenic activities. It effectively scavenged intracellular and extracellular free radicals, reduced inflammatory cytokine levels, and inhibited melanin synthesis. Molecular docking and gene expression analyses suggested that its anti-melanogenic effect might be associated with the MC1R/cAMP/MITF signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.